 SAN DIEGO, Sept. 20, 2021 PRNewswire -- Mirati Therapeutics, Inc. NASDAQ: MRTX, a clinical-stage targeted oncology company, today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small cell lung cancer NSCLC harboring the KRAS G12C mutation following prior systemic therapy. 